Neurosoft Bio awarded 2.5 MCHF Swiss Accelerator Grant
Neurosoft Bioelectronics was selected by Innosuisse as one of 53 projects (out of 752 applicants) and will receive funding to continue development of innovative minimally-invasive Brain Computer Interfaces.
Neurosoft Bioelectronics was selected as one of 53 projects (out of 752 applications) and will receive funding to continue development of innovative minimally-invasive Brain Computer Interfaces.
Innosuisse launched a call for projects for the Swiss Accelerator in 2022 as a transitional measure for Horizon Europe. Following a three-stage assessment process, Innosuisse has now approved 53 innovation projects by SMEs and start-ups with significant innovation potential.
Three independent experts evaluated each of the 752 short applications and the 128 full applications. Of these, 64 selected companies gave an application presentation in the third round before the Innovation Council made a final decision. The total funding granted amounts to CHF 112 million.
The 53 approved innovation projects within the framework of the Swiss Accelerator are divided thematically as follows:
- 20 in Life Sciences, 8 in Engineering, the rest being spread across Energy & environment, ICT and Social sciences and business management
- One third are from the French speaking part of Switzerland (other two thirds from the German speaking part)
Congratulations for this new milestone on the path to making the Neurosoft Bioelectronics technology to patients!